pharmaphorum August 23, 2024
Just a few months after raising $200 million in third-round financing, immunology specialist Zenas BioPharma has filed an initial public offering in the US seeking to add another $100 million to the pot.
The five-year-old Waltham, Massachusetts-based company is developing a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, called obexelimab, which is in a phase 3 trial as a treatment for IgG4-related disease (IgG4-RD), phase 2/3 in warm autoimmune haemolytic anaemia (wAIHA), and phase 2 in multiple sclerosis (MS) and systemic lupus erythematosus (SLE).
Zenas acquired worldwide rights to obexelimab from its original developer Xencor in a $480 million deal agreed in 2021. The drug was a flagship project at Xencor until it failed a phase 2 trial in SLE...
Today's Sponsors
Today's Sponsor